{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-008711","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2025-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.490534+00:00","generated_at":"2026-05-19T03:11:05.416360+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Scholar Rock Phase 2 EMBRAZE trial shows 54.9% lean mass preservation with apitegromab plus tirzepatide (p=0.001)","bullets":["Primary endpoint met: apitegromab + tirzepatide preserved 54.9% of lean mass (p=0.001) vs tirzepatide alone over 24 weeks.","Patients on combination lost 18.8 lbs fat mass vs 17.7 lbs for tirzepatide alone; total weight loss 12.3% vs 13.4%.","Quality of weight loss improved: 85% fat / 15% lean mass loss with combination vs 70% fat / 30% lean with tirzepatide alone.","Apitegromab well tolerated; no SAEs or discontinuations related to apitegromab, consistent with prior studies.","Company plans to file IND for next-gen SRK-439 in H2 2025; conference call today at 8 AM EDT."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-008711","json":"https://secwatch.observer/filing/0001558370-25-008711.json","markdown":"https://secwatch.observer/filing/0001558370-25-008711.md","text":"https://secwatch.observer/filing/0001558370-25-008711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000155837025008711/0001558370-25-008711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000155837025008711/srrk-20250618x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T03:11:05.416360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}